Recurrent implantation failure (RIF), defined as the absence of clinical pregnancy after the transfer of three good-quality embryos, concerns up to 40% of IVF couples and is associated with a low success rate. The causes remain unexplained in over 50% of cases.
Various dysimmune changes (related to immune T cells profiles, pro-inflammatory cytokines levels) have been described in unexplained RIF as compared to fertile controls, and it has been estimated that such dysimmunity may occur in 50% of unexplained RIFs. Previous data on a benefit of general immune modulation by steroids or immunoglobulins are heterogenous and failed to demonstrate clinically significant benefit. The proinflammatory cytokine Tumor Necrosis Factor (TNF) α participates in the regulation of the immune balance of the endometrium, its peripheral blood and endometrial concentrations are increased in RIF patients as compared to fertile controls. In 2009, a pilot placebo controlled study showed that TNF-α antagonist treatment allowed a 56% live birth rate (versus 13% in controls) in 13 women with unexplained RIF. Due to the lack of maternal and fetal tolerance data, TNF-α antagonists were not further evaluated. Today, safety data issued from 1200 pregnancies are reassuring allowing the use of TNF-α antagonists during pregnancy (www.lecrat.org). In addition the TNF-α antagonist certolizumab does not cross the placental barrier.
We hypothesize that certolizumab may improve clinical pregnancy rates in women with unexplained RIF with a good safety profile.

Start Date30 Nov 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT06028438

/ CompletedPhase 2

A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of Concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Despite Prior Treatment With Advanced Therapies (bDMARD or tsDMARD)

The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.

Start Date15 Aug 2023

Sponsor / Collaborator

Janssen Research & Development LLC

NCT05115903

/ Active, not recruitingPhase 4IIT

A Prospective, Randomized Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

Current evidence on tapering of tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) is still hampered by heterogeneity in tapering regimens, selection and performance biases, and lack of data on optimized treatment dosing strategies especially in real-world clinical settings. This study aims to contribute to the ongoing investigation of disease-activity-guided tapering of TNFi in axSpA in the form of a prospective, randomized controlled trial.

Start Date01 Dec 2021

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Certolizumab Pegol

100 Translational Medicine associated with Certolizumab Pegol

100 Patents (Medical) associated with Certolizumab Pegol

1,669

Literatures (Medical) associated with Certolizumab Pegol

01 May 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The use of aptamers as therapeutic inhibitors and biosensors of TNF-alpha

Review

Author: Sahebkar, Amirhossein ; Kesharwani, Prashant ; Abianeh, Hossein Samiei

Tumor necrosis factor-alpha (TNF-α) is a pivotal cytokine in the pathogenesis of numerous inflammatory and autoimmune diseases. Precise and sensitive detection of TNF-α is essential for both clinical applications and research endeavors. In the realm of cytokine detection, particularly TNF-α, the development of highly sensitive and specific biosensors has become a focal point. The biosensing landscape encompasses a variety of biorecognition elements, each with its unique set of characteristics. TNF inhibitors come with a significant price tag and, notably, do not yield positive responses in all patients. Despite the availability of numerous FDA-approved biologic agents (e.g., infliximab, adalimumab, certolizumab pegol, etc.) and monoclonal antibodies (e.g., adalimumab) targeting TNF-α, aptamers tailored for blocking TNF-α activities have yet to receive approval. Aptamers have rapidly gained recognition as readily available, versatile, and highly effective molecular tools for both therapeutic and diagnostic purposes in the context of TNF-alpha. In this manuscript, we explore the potential of short single-stranded DNA or RNA sequences known as aptamers as biorecognition elements in biosensors designed for the detection of TNF-α. We delve into the progress made in the development of aptamer-based TNF-α inhibitors and shed light on successful studies in this burgeoning field.

01 Mar 2025·JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden

Article

Author: Passey, A. ; Wennerström, C. ; Johnsson, I. ; Hoti, F. ; Mälkönen, T. ; Katus, U. ; Hermanrud, C. ; Westerlund, A. ; Sveide, I. ; Hassan, F. ; Polesie, S. ; Tskhvarashvili, G. ; Saarelainen, L. ; Aher, K. ; Lee, J. ; Nissinen, R.

Abstract:

Background:

Plaque psoriasis (PsO) requires long‐term treatment for symptom control and remission; thus, a long‐term pharmacological intervention is necessary. Treatment persistence reflects long‐term therapeutic effectiveness and tolerance.

Objectives:

This study investigates drug persistence and compares treatment discontinuation rates across biologic agents and apremilast used by PsO patients in Finland and Sweden.

Methods:

This retrospective register‐based cohort study included bio‐naïve patients (≥18 years) with moderate‐to‐severe PsO, who initiated treatment with abatacept, adalimumab, brodalumab, certolizumab pegol, etanercept, golimumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab or apremilast during 2008–2020 in Finland or Sweden. The main analysis evaluated persistence (based on duration of continuous treatment) and compared rates of treatment discontinuation using guselkumab as reference drug, during 2018–2020 in Finland. Treatment discontinuation was assessed by survival analysis of the time to first drug discontinuation, including switching to other study drugs. Due to limited sample size (n < 20), certain biologics (abatacept, brodalumab, certolizumab pegol, etanercept, golimumab, risankizumab and tildrakizumab) were excluded from the persistence analysis.

Results:

In Finland, 709 patients fulfilled the inclusion criteria during 2018–2020 for the main analysis. The highest persistence was observed for guselkumab and ustekinumab with 90 and 85% of treated patients, respectively, continuing treatment for ≥1 year. Comparable results were observed in the expanded cohort analysis (index starting in 2008; 2745 bio‐naïve patients in Finland and 10,970 in Sweden). Furthermore, patients treated with guselkumab in Finland showed lower treatment discontinuation rates compared to other study drugs.

Conclusion:

Guselkumab and ustekinumab demonstrated high persistence as measured by continued treatment for at least 1 year. Furthermore, these treatments demonstrated lower rates of discontinuation compared to other study drugs included in the analysis. Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates.

01 Mar 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Deep ultraviolet Raman spectroscopic analysis of antihistamine drugs in oral fluid for forensic purposes

Article

Author: Amin, Mohamed O ; Rossi, Barbara ; Al-Hetlani, Entesar ; Matroodi, Fatima ; Lednev, Igor K

Owing to its inherent nondestructive nature, rapid analysis and simplicity, Raman spectroscopy has emerged as a promising tool for forensic analysis of different bodily fluids, particularly oral fluid (OF). Accurate drug identification and quantification are essential for understanding the circumstances surrounding a case, such as whether it involves an overdose fatality, substance abuse, or drug trafficking. This study aims to evaluate the potential of using deep ultraviolet Raman spectroscopy (DUVRS) to detect the antihistamine cetirizine (CTZ) in liquid and solid OF samples. The application of DUVRS facilitated CTZ detection in liquid OF samples with a limit of detection (LOD) of 50 µg/mL. Additionally, integrating multivariate statistical analysis with DUVRS enabled reliable differentiation between pure OF stains and those contaminated with CTZ, thereby demonstrating its high sensitivity for CTZ detection. Further method development is warranted, involving larger cohorts of donors, increased numbers of samples, and a broader range of drug types, to enhance the practicality of this approach for forensic applications.

News (Medical) associated with Certolizumab Pegol

20 Mar 2025

·pipelinereview.com

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

REYKJAVIK, Iceland and STOCKHOLM, Sweden I March 20, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane’s R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other pre-clinical assets and will focus on the commercialization of this portfolio. Alvotech also announced that it intends to explore the possibility of a listing of Swedish Depository Receipts (SDR), equity share equivalents, on Nasdaq Stockholm, in the future. The acquisition in brief “Alvotech has a best-in-class biosimilars manufacturing site in Iceland, both for drug substance and drug products. At the same time, our strong in-house R&D capabilities have put Alvotech in a leading position among pure play biosimilar companies in terms of the market value of our product pipeline. This acquisition will further expand Alvotech’s development capacity, allowing our commercial network of 19 leading commercial partners worldwide to continue increasing patient access to quality biologics,” said Robert Wessman, founder, Chairman and CEO of Alvotech. “Furthermore, we will establish a strong presence for Alvotech in the Swedish life science sector, which rivals the U.S. in this field. It will allow Alvotech to attract new talent, create opportunities for scientific collaboration, and support our growth. This is yet another milestone for Alvotech in establishing us as a leader in biosimilars development and production globally.” “With this transaction Xbrane is significantly strengthening its financial position and retains over 75% of the competitively adjusted addressable market of the portfolio including Ximluci (Lucentis biosimilar candidate) currently being approved and sold in Europe as well as Xdivane (Opdivo biosimilar candidate), recently partnered with Intas. Xbrane will, with a more lean and flexible organization after the transaction, be better equipped to fully focus on realizing the full value of Ximluci and Xdivane with the ambition to generate meaningful royalties/profit sharing from these programs in the years to come,” said Martin Åmark, CEO of Xbrane. Headquartered in Reykjavik, Iceland, Alvotech’s shares are listed on Nasdaq Iceland and Nasdaq US. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Since 2013, Alvotech has invested about $1.9 billion in a purpose-built biosimilars R&D and manufacturing platform, established commercial partnerships with 19 leading companies in over 90 of the largest global markets and developed one of the most valuable portfolios in the biosimilars industry. Advisors DNB Carnegie is acting as financial advisor to Alvotech in connection with the Acquisition. Cirio and Westerberg are legal advisors to Alvotech in connection with the Acquisition. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com . None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube . SOURCE: Alvotech

AcquisitionDrug ApprovalBiosimilar

29 Oct 2024

·www.prnewswire.com

Genascence Appoints Jeymi Tambiah as Chief Medical Officer

—Accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience in medical affairs, clinical development, and drug development —Visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in areas of osteoarthritis, immunology, oncology, and neuroscience PALO ALTO, Calif., Oct. 29, 2024 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Jeymi Tambiah, MBChB, FRCS, MS, FAPCR, MFPM(Dis) as its chief medical officer. Dr. Tambiah is an accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience creating and leading strategies for medical affairs, clinical development, and drug development programs. He also brings deep experience in translational medicine, commercialization, and health outcomes research to Genascence. Continue Reading Jeymi Tambiah, Chief Medical Officer, Genascence "Jeymi is a visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in the areas of osteoarthritis, immunology, oncology, and neuroscience and I am excited to welcome him to Genascence as our chief medical offer," said Thomas Chalberg, Ph.D., founder and CEO of Genascence. "His experience includes all phases of drug development from bench through Phase 1-4 clinical studies and building elite high performance medical affairs teams. Jeymi's development and research expertise, particularly within the osteoarthritis research community, will be invaluable as we execute on our strategy to bring gene therapy to people suffering from prevalent musculoskeletal diseases." "Genascence is a company that is transforming how we treat debilitating musculoskeletal diseases like osteoarthritis by pioneering the development of gene therapy," said Dr. Tambiah. "I am thrilled to join this outstanding team under Tom's leadership and apply my knowledge and experience to advance our clinical program so that we can bring potentially curative therapies to patients in desperate need of better treatments." Before joining Genascence, Jeymi was senior vice president of clinical development and external innovation at Biosplice Therapeutics, a start-up biotech developing molecules modulating mRNA splicing in oncology, arthritis, and neurodegenerative diseases, where he was primarily responsible for clinical development, medical affairs, and external thoughtleader and scientific partnerships. Previously, Jeymi worked for UCB Pharma in various roles of increasing leadership within medical affairs, launching the TNF-inhibitor certolizumab pegol within the European Union, U.K., and U.S. across multiple immunology indications. Before his move into pharma, Jeymi trained and practiced in cardiothoracic surgery at Guys' and St. Thomas' Hospitals in London. Jeymi is very active in the osteoarthritis research community, with numerous research awards and publications, holding many committee appointments, and regularly presenting at international conferences. He is the North American representative for the Faculty of Pharmaceutical Medicine UK, and in this role is dedicated to supporting the education and mentoring of physicians in drug development. Jeymi earned his medical degree from the University of Manchester, UK, a doctorate degree in vascular biology from Imperial College London where he was a Wellcome Research Fellow, and a BSc (Hons) in medical science from the University of St. Andrews, UK. He is a fellow of the Royal College of Surgeons of England and Edinburgh, a member of Faculty of Pharmaceutical Physicians UK by Distinction, and a fellow of the Academy of Physicians in Clinical Research. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit . SOURCE Genascence WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeGene Therapy

22 Jul 2024

·healthcare-digital.com

Research Breakthrough Promises New Lupus Treatments

The purple ribbon denotes World Lupus Day, May 10. As study of patients with lupus uncovers a root cause of the condition we take a deeper look at the autoimmune disease and how it is currently treated A study of patients with lupus has uncovered a root cause of the disease that may eventually lead to new treatments, researchers reported in a study published in Nature. The immune disorder affects more than 1.5 million people in the US alone, and damages skin, joints, the kidneys, the brain and other organs. Comparing blood samples from 19 patients suffering from lupus with healthy people, researchers found that the patients had an imbalance in immune-system cells called ‘T cells’. There was reduced production of T cells that aid in healing, and increased production of T cells that produce autoantibodies to attack healthy cells. In the wake of the study, we take a look at lupus – at its effects and the available treatments. What is lupus? Lupus is an autoimmune disease that causes the body's immune system to attack its own tissues and organs. This condition can affect various parts of the body, including skin, joints, kidneys, brain, heart and lungs. Diagnosis can be complex, as symptoms often mimic those of other ailments. Treatment options for lupus depend on the severity of symptoms and which organs are affected. The cause of lupus remains unknown, but researchers believe it involves a combination of genetic and environmental factors. Women are more likely to develop lupus than men, and it is more prevalent in certain ethnic groups. Patients with lupus are advised to protect themselves from sun exposure, as ultraviolet light can trigger flares in some individuals. How is lupus treated? Medications include anti-inflammatory drugs, antimalarial drugs and immunosuppressants. Research has shown antimalarial drugs such as hydroxychloroquine and chloroquine can decrease the frequency and severity of lupus flare-ups. They work by modulating the immune system, which is overactive in lupus patients. This helps reduce inflammation and pain, particularly in the skin and joints. These medications also help protect the heart, and are thought to lower the risk of blood clots in lupus patients. This is significant as individuals with lupus have an increased risk of cardiovascular complications. Antimalarials are used in combination with immunosuppressants for more severe cases. Immunosuppressants are used to treat lupus because the condition results in the body's immune system mistakenly attacking healthy tissue, causing inflammation and damage to organs including the kidneys, heart and lungs. Common immunosuppressants used in lupus treatment include methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide. These can be administered orally or intravenously, depending on the specific drug and the patient's condition. The use of immunosuppressants carries risks, as a suppressed immune system makes the patient more susceptible to infections. Companies that specialise in lupus medicines Medications used to treat lupus include anti-inflammatory drugs, antimalarial drugs and immunosuppressants. The following are among the companies that produce treatments in these three categories. Immunosuppressants GlaxoSmithKline : Benlysta (based on belimumab) AstraZeneca : Saphnelo (anifrolumab-fnia) Aurinia Pharmaceuticals: Lupkynis (voclosporin) Roche : Rituxan (rituximab) Bristol Myers Squibb : Orencia (abatacept) Eli Lilly : Olumiant (baricitinib) Pfizer : Xeljanz (tofacitinib) Antimalarials Sanofi : Plaquenil (hydroxychloroquine) Anti-inflammatories Novartis : Ilaris (canakinumab) Janssen Pharmaceuticals: Remicade (infliximab) UCB: Cimzia (certolizumab pegol)

ImmunotherapyDrug Approval

100 Deals associated with Certolizumab Pegol

External Link

KEGG	Wiki	ATC	Drug Bank
D03441	Certolizumab Pegol	L04AB05	DB08904

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erythrodermic psoriasis	Japan	UCB Japan Co. Ltd.	20 Dec 2019
Psoriasis vulgaris	Japan	UCB Japan Co. Ltd.	20 Dec 2019
Pustular psoriasis	Japan	UCB Japan Co. Ltd.	20 Dec 2019
Non-radiographic axial spondyloarthritis	Australia	UCB Australia Pty Ltd.	20 Jan 2010
Plaque psoriasis	Australia	UCB Australia Pty Ltd.	20 Jan 2010
Ankylosing Spondylitis	European Union	UCB Pharma GmbH	01 Oct 2009
Ankylosing Spondylitis	Iceland	UCB Pharma GmbH	01 Oct 2009
Ankylosing Spondylitis	Liechtenstein	UCB Pharma GmbH	01 Oct 2009
Ankylosing Spondylitis	Norway	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	European Union	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	Iceland	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	Liechtenstein	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	Norway	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	European Union	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	Iceland	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	Liechtenstein	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	Norway	UCB Pharma GmbH	01 Oct 2009
Rheumatoid Arthritis	United States	UCB, Inc.	13 May 2009
Crohn Disease	United States	UCB, Inc.	22 Apr 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis	Phase 3	Belgium	UCB SA	30 Jan 2022
Crohn's disease, active moderate	Phase 3	United States	UCB Biopharma SRL	03 Nov 2017
Generalized Pustular Psoriasis	Phase 3	Japan	UCB Biopharma SRL	21 Feb 2017
Cystitis, Interstitial	Phase 3	United States	UCB Pharma GmbH	15 Dec 2015
Inflammation	Phase 3	United States	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Australia	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Bulgaria	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Canada	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Czechia	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Hungary	UCB BioSciences GmbH	01 Sep 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00844285 (SECURE Registry, Pubmed \| Crohns Colitis 360)	Not Applicable	Crohn Disease	3,072	Certolizumab Pegol (CZP)	sxqubuavqe(oqmdywnfhc) = concomitant use of thiopurines was associated with higher odds of NMSC (odds ratio: 2.30 [95% CI: 1.09, 4.89]) bnvlpujprr (erufrpjvwn ) View more	Positive	30 Dec 2024
				Corticosteroids
NCT04163016 (CHERISH, CTgov)	Phase 1	Plaque psoriasis \| Arthritis, Psoriatic \| Inflammation ... View more	22	CZP (CZP 200 mg Q2W)	lwowazixrj(jfruopouzn) = lcrnqtsnxn jentbzlytu (lpfnaspuyl, 68.1) View more	-	19 Sep 2024
				CZP (CZP 400 mg Q2W)	zjnjcxvahk(kdpnrfjxeu) = viiynhfbyw ptkdauzqod (xrmkxzyfjx, hvzoquwiiz - lexfiffhum) View more
NCT04053881 (CIMREAL, Pubmed)	Not Applicable	Plaque psoriasis tumor necrosis factor alpha (TNFα)	399	Certolizumab pegol 400 mg	hxmrrfruec(oerkxbdlzo) = iluecaiuom jhmlrqyczm (hxjgyqhdjq ) View more	Positive	27 Jun 2024
				Certolizumab pegol 200 mg	hxmrrfruec(oerkxbdlzo) = rjshjuvhej jhmlrqyczm (hxjgyqhdjq ) View more
NCT04163016 (CHERISH, EULAR 12024 \| EULAR 22024) Manual	Phase 1	Autoimmune Diseases	21	CERTOLIZUMAB PEGOL	guhchsfert(rfcicnxumi) = leuhwwvdcj fvbywpxksr (skpouwfyks )	Positive	14 Jun 2024
EULAR2024	Not Applicable	Axial Spondyloarthritis	-	Certolizumab	znpiejxuzp(hnrlxetqgo) = khljyyummy bksjgfyxbz (babiwtapqd )	Positive	05 Jun 2024
				Secukinumab	znpiejxuzp(hnrlxetqgo) = lrlztsajhk bksjgfyxbz (babiwtapqd )
Apulian BIOPURE registry (EULAR2024)	Not Applicable	Chronic arthritis	542	Certolizumab (Fertile female patients)	mioegbkedy(aydmntutwn) = htrkhhxvom vorqqgejkx (jknuhbrxat ) View more	Positive	05 Jun 2024
				Certolizumab (Menopausal female patients)	mioegbkedy(aydmntutwn) = japrikddhs vorqqgejkx (jknuhbrxat ) View more
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	cdbjsizvhk(dsxkwncbym) = zxriiinypd lguvljcpto (umlhefpfhc )	Positive	05 Jun 2024
				Infliximab (IFX)	cdbjsizvhk(dsxkwncbym) = cqcdprrbbs lguvljcpto (umlhefpfhc )
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Biologic and targeted synthetic DMARDs	pzcpmgyvuh(ibvnzuuhfx) = mwqkwnixkc horbpahpvq (eewuwmgeav ) View more	-	05 Jun 2024
NCT01500278 (EXXELERATE, ACR2023) Manual	Phase 4	Rheumatoid Arthritis	907	Certolizumab Pegol+Methotrexate	zkxzccotnn(qadruxecsj) = hywvubrabg ngaqkrtmuf (iwopfpohax ) View more	Non-superior	14 Nov 2023
				Adalimumab+Methotrexate	zkxzccotnn(qadruxecsj) = bstpjceggw ngaqkrtmuf (iwopfpohax ) View more
ACR2023	Not Applicable	Rheumatoid Factor (RF)	755	Certolizumab Pegol	fsyqzoiizu(asiomdcvkz) = nndzoccuaj slbguxpfny (dkwqgcbkvh, 3.7 - NA)	Positive	13 Nov 2023
				Monoclonal Antibodies (mAB)	fsyqzoiizu(asiomdcvkz) = igtmpqclzq slbguxpfny (dkwqgcbkvh, 3.3 - 8.7)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis